Efavirenz News and Research

RSS
Efavirenz, also known as EFV or Sustiva, is a type of medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Efavirenz was approved by the FDA on September 17, 1998, for use with other antiretroviral agents in the treatment of HIV infection in adults and children ages 3 and older. This medicine does not cure HIV infection or AIDS and does not reduce the risk of passing the virus to other people. Efavirenz may also be used with other antiretroviral medications to prevent HIV in people who have been exposed to the virus in the work place, such as health care providers who come in contact with HIV infected blood through an accidental needle stick.
Brazil to produce generic version of Merck's antiretroviral Efavirenz

Brazil to produce generic version of Merck's antiretroviral Efavirenz

Genetic screening effective for initial HIV treatment

Genetic screening effective for initial HIV treatment

Certain HIV treatment less effective when used with rifampicin-based anti-tuberculosis therapy

Certain HIV treatment less effective when used with rifampicin-based anti-tuberculosis therapy

Merck announces significant price cuts on two of its AIDS drugs, Stocrin and Isentress

Merck announces significant price cuts on two of its AIDS drugs, Stocrin and Isentress

Access to generic HIV/AIDS drugs increasing following Thailand's decision to issue compulsory licenses, health official Says

Access to generic HIV/AIDS drugs increasing following Thailand's decision to issue compulsory licenses, health official Says

Ardea Biosciences completes phase 1 trials of HIV drug RDEA806

Ardea Biosciences completes phase 1 trials of HIV drug RDEA806

New trade agreement language to allow developing countries more flexibility in circumventing drug patents, other restrictions

New trade agreement language to allow developing countries more flexibility in circumventing drug patents, other restrictions

Clinton to the rescue again!

Clinton to the rescue again!

U.S. trade rep places Thailand on priority watch list in annual report

U.S. trade rep places Thailand on priority watch list in annual report

Health advocates, drug industry reps lobby lawmakers for support in Thailand drug licensing dispute

Health advocates, drug industry reps lobby lawmakers for support in Thailand drug licensing dispute

Brazilian Health Minister says country will purchase generic version of Merck antiretroviral if price not lowered

Brazilian Health Minister says country will purchase generic version of Merck antiretroviral if price not lowered

Thailand wins round two in battle to access cheaper AIDS drugs

Thailand wins round two in battle to access cheaper AIDS drugs

Thailand threatens big pharma companies

Thailand threatens big pharma companies

Public standards for world medications to treat neglected infectious diseases

Public standards for world medications to treat neglected infectious diseases

Thai Health Ministry to issue compulsory license for Merck's HIV/AIDS drug Efavirenz

Thai Health Ministry to issue compulsory license for Merck's HIV/AIDS drug Efavirenz

Bristol-Myers Squibb receives FDA approval for new formulation of antiretroviral Reyataz

Bristol-Myers Squibb receives FDA approval for new formulation of antiretroviral Reyataz

FDA approves Atripla for the treatment of HIV-1 infection in adults

FDA approves Atripla for the treatment of HIV-1 infection in adults

FDA approves Atripla three-drug combination tablet for treatment of HIV-1

FDA approves Atripla three-drug combination tablet for treatment of HIV-1

Clinton's deal with drug companies will save millions of lives and millions of dollars

Clinton's deal with drug companies will save millions of lives and millions of dollars

Depression appears to be a major cause of insomnia in people with HIV

Depression appears to be a major cause of insomnia in people with HIV